Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 5, 2007 - Issue 1
Submit an article Journal homepage
127
Views
6
CrossRef citations to date
0
Altmetric
Review

Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

Bruce E Lewis Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA. [email protected]
&
Marcie J Hursting Clinical Science Consulting, 3001 Loveland Cove, Austin, TX 78746, USA. [email protected]
Pages 57-68 | Published online: 10 Jan 2014

References

  • Rice L. Heparin-induced thrombocytopenia. Myths and misconceptions (that will cause trouble for you and your patient). Arch. Intern. Med.164, 1961–1964 (2004).
  • Jang IK, Hursting MJ. When heparins promote thrombosis: a revie of heparin-induced thrombocytopenia. Circulation111, 2671–2683 (2005).
  • Kelton JG. The pathophysiology of heparin-induced thrombocytopenia. Biological basis for treatment. Chest127, 9S–20S (2005).
  • Francis JL, Palmer GJ, Moroose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg75, 17–22 (2003).
  • Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann. Thorac. Surg76, 638–648 (2003).
  • Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl), 311S–337S (2004).
  • Warkentin TE, Sheppard JAI, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia Blood online ahead of print (2006).
  • Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107, 2307–2312 (2003).
  • Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital. Heart J.1, 39–42 (2000).
  • Bennett-Guerrero E, Slaughter TF, White WD etal. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J. Thorac. Cardiovasc. Surg.130, 1567–1572 (2005).
  • Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med.344, 1286–1292 (2001).
  • Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch. Intern. Med.164, 361–369 (2004).
  • LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit. Care Med.32, 976–980 (2004).
  • Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129, 1407–1416 (2006).
  • Fabris F, Luzzatto G, Soini B, et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J. Intern. Med.252, 149–154 (2002).
  • Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am. J. Hematol.76, 240–244 (2004).
  • Das P, Ziada K, Steinhbubl SR, et al. Heparin-induced thrombocytopenia and cardiovascular diseases. Am. Heart J. 152, 19–26 (2006).
  • Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation103, 1838–1843 (2001).
  • Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Int. Med.163, 1849–1856 (2003).
  • Greinacher A, Volpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation99, 73–80 (1999).
  • Greinacher A, Janssens U, Berg G et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation100, 587–593 (1999).
  • Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J. Thromb. Haemost.3, 2428–2436 (2005).
  • Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet. Cardiovasc. Interv.57, 177–184 (2002).
  • Mahaffey KW, Lewis BE, Wildermann NM et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J. Invasive Cardiol.15, 611–616 (2003).
  • Argatroban Prescribing Information. Research Triangle Park NC: GlaxoSmithKline; 2005.
  • Angiomax® Prescribing Information. Parsippany NJ: The Medicines Company; 2005.
  • Refludan® Prescribing Information. Wayne and Montville NJ: Berlex Laboratories Inc; 2004.
  • Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J. Thorac. Cardiovasc. Surg.13, 699–700 (2006).
  • De Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann. Pharmacother.37, 1237–1240 (2003).
  • Baghdasarian S, Singh I, Militello M, Bartholomew J, Begelman S. Argatroban dosage in critically ill patients with HIT [abstr]. Blood104, 493a (2004).
  • Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest129, 1167–1175 (2006).
  • Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy26, 452–460 (2006).
  • Tardy B. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood108, 1492–1496 (2006).
  • Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT and clinical relevance. Blood 96, 2373–2378 (2000).
  • Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb. Haemost.95, 967–981 (2006).
  • Harenberg J, Jorg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica89, 1017–1018 (2004).
  • Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 101, 21–37 (2003).
  • Matthai WH, Lewis BE, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb. Res.116, 121–126 (2005).
  • DeEugenio DL, Ruggiero N, Thomson LJ, Menajovsky LF, Herman JH. Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature. Pharmacotherapy25, 615–619 (2005).
  • Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest 127, 1S–8S (2005).
  • Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br. J. Haematol.133, 259–269 (2006).
  • Foo SY, Everett BM, Yeh R et al. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am. Heart J.152, 290 e1–7 (2006).
  • Gluckman TJ, Segal JB, Fredde NL et al. Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am. J. Cardiol.95, 744–7 (2005).
  • Cruz D, Karlsberg R, Takano Y, Vora D, Tobis J. Subacute stent thrombosis associated with heparin-coated stent and heparin-induced thrombocytopenia. Catheter Cardiovasc.Interv.58, 80–83 (2003).
  • McNutly I, Katz E, Kim KY. Thrombocytopenia following heparin flush. Progress Cardiovasc. Nurs.20, 143–147 (2005).
  • Manfredi JA, Wall RP, Sane DC, Braden GA. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports. Cathet. Cardiovasc. Interv.52, 468–472 (2001).
  • Pinto DS, Sperling RT, Tu RM, Cohen DJ, Carrozza JP. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc. Interv.58, 65–68 (2003).
  • Cochran K, DeMartini TJ, Lewis BE, et al. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. J. Invasive Cardiol.15, 617–621 (2003).
  • Smith S, Feldman TE, Hirshfeld JW et al ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 113, 156–175 (2006).
  • Jang IK, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J. Thromb. Thrombolysis18, 31–37 (2004).
  • Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J. Pediatr. Hematol. Oncol.28, 4–10 (2006).
  • Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am. Heart J. 142, 952–959 (2001).
  • Lincoff AM, Bittl JA, Harrington RA et al Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA289, 853–63 (2003).
  • Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 25,1736–1745 (2005).
  • Frame JN. The heparin-induced thrombocytopenia task force model: implementing quality improvement and economic outcome initiatives. Semin. Hematol.42, s28–S35 (2005).
  • Arnold RJ, Kim R, Tang B. The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment. Cardiol. Rev.14, 7–13 (2006).
  • Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy26, 461–468 (2006).
  • Koster A, Hansen R, Kupps H, Hetzer R, Crystal GJ, Metzlufft F. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J. Cardiothorac. Vasc. Anesth.14, 243–248 (2000).
  • Laber A, Martin E, Kloecker H. Proposed guidelines for anticoagulation during cardiac surgery using argatroban [abstract]. Haematol. 91(Suppl 1), 151–152 (2006).
  • Dyke CM, Koster A, Veale JJ, Maier GW, McNiff T, Levy JH. Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann. Thorac. Surg.80, 299–303 (2005).
  • Dyke CM, Smedira NG, Koster A et al A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J. Thorac. Cardiovasc. Surg.131, 533–539 (2006).
  • Smedira NG, Dyke CM, Koster A et al Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J. Thorac. Cardiovasc. Surg.131, 686–692 (2006).
  • Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation108, 2062–2065 (2003).
  • Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 103, 613–616 (2004).
  • LaMonte MP, Brown PM, Hursting MJ. Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor. Expert Rev. Cardiovasc. Ther.3, 31–41 (2005).
  • Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy22(6 pt 2), 105S–111S (2002).
  • Honikso ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am. J. Health Syst. Pharm.61, 2415–2418 (2004).
  • Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am. J. Health Syst. Pharm.61, 1774–1776 (2004).
  • Gosselin RC, Dager WE, King JH et al Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am. J. Clin. Pathol.121, 593–599 (2004).
  • Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin. Appl. Thromb. Hemost.11, 279–287 (2005).
  • Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb. Haemost. 85, 435–440 (2001).
  • Harder S, Graff J, Klinkhardt U et al Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb. Haemost. 91, 1137–1145 (2004).
  • Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy25, 157–164 (2005).
  • Fischer KG. Hirudin in renal insufficiency. Semin. Thromb. Hemost.28, 467–482 (2002).
  • Murray PM, Reddy BV, Grossman EJ et al. A prospective comparison of three argatroban treatment regimens during in end-stage renal disease. Kidney Int. 66, 2446–2453 (2004).
  • Alsoufi B, Boshkov LK, Kirby A et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu.7, 155–171 (2004).
  • Stratmann G, diSilva AM, Tseng EE et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth. Analg. 98, 1635–1639 (2004).
  • Yee AJ, Kuter DJ. Successful recovery from an overdose of argatroban. Ann. Pharmacother.40, 446–449 (2006).
  • Hallman SE, Hebbar L, Robinson J, Uber WE. The use of argatroban for carotid endarterectomy in heparin-induced thrombocvtopenia. Anesth. Analg.100, 946–948 (2005).
  • Finks SW. Bivalirudin use in carotid endarerectomy in a patient with heparin-induced thrombocytopenia. Ann. Pharmacother.40, 340–3 (2006).
  • Itoh T, Nonogi H, Miyasaki S et al. Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: a prospective randomized pilot study.Circ. J. 68, 615–622 (2004).

Website

  • The CHOOSE-ON and CHOOSE-OFF Pump Trials. The future of Angiomax. Available at www.angiomax.com/ClinicalInfo/futureAngiomax.aspx Accessed September 27, 2006.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.